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Abstract
It is now well established that major depression is accompanied and characterized by altered responses of the immune-
inflammatory system. In this study we investigated the pro-inflammatory activation of monocytes isolated from depressed
patients as a parameter not influenced by such confounds as the time of day, the nutritional and exercise status or the age
and gender of patients. Monocytes from depressed patients and from healthy controls were isolated in vitro; after 24-h
incubation under basal conditions, cells were exposed for 24-h to 100 ng/ml of endotoxin (bacterial lipopolysaccharide,
LPS). We found that monocytes from drug-free depressed patients and controls release the same amounts of prostaglandin
E2 (PGE2) under basal conditions, whereas monocytes from patients are dramatically less reactive to LPS (8.62-fold increase
vs previous 24 hrs) compared to healthy controls (123.3-fold increase vs previous 24 hrs). Such blunted prostanoid
production was paralleled by a reduction in COX-2 gene expression, whereas other pro-inflammatory mediators, namely
interleukin-1b (IL-1 b) and -6 (IL-6) showed a trend to increased gene expression. The above changes were not associated to
increased levels of circulating glucocorticoids. After 8 months of antidepressive drug treatment, the increase in PGE2
production after the endotoxin challenge was partially restored, whereas the increase in IL-1 b and -6 levels observed at
baseline was completely abolished. In conclusion, our findings show that the reactivity of monocytes from depressed
patients might be considered as a marker of the immune-inflammatory disorders associated to depression, although the
lack of paired healthy controls at follow-up does not allow to conclude that monocyte reactivity to endotoxin is also a
marker of treatment outcome.
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Introduction
Major depressive disorder (MDD) is a severe and potentially
debilitating psychiatric illness characterized by significant changes
in mood. MDD frequently presents with a chronic course and can
result in marked individual suffering and disability [1]. Evidence
collected over the last 40 years indicates that disturbances in
serotonergic and noradrenergic neurotransmission are a pivotal
factor in the pathogenesis of MDD. Although the roles of
serotonin and noradrenalin neuronal systems have extensively
been studied, certain aspects of MDD patho-physiological
mechanism remain to be clarified [2].
Proinflammatory cytokines are involved in a variety of
behavioral, neuroendrocrine and neurochemical alterations that
accompany MDD [3]. Accordingly, elevations in circulating pro-
inflammatory cytokines and other inflammation-related proteins
are a well-documented finding [4]. In particular, prostaglandin
(PG) E2 is a product of the arachidonic acid cascade that enhances
its own production but suppresses acute inflammatory mediators,
resulting in its predominance at late/chronic stages of immune
response [5]. Increased PGE2 levels were observed in saliva [6],
cerebrospinal fluid and serum [7,8] of depressed patients.
So far, no standardized test has been developed to use plasma,
serum or saliva levels of inflammatory mediators as a possible
marker of illness or treatment response in MDD, probably because
of methodological difficulties in the measurement of these
parameters. In fact, cytokines and PGE2 concentrations in
biological fluids are influenced by a huge variety of factors,
including timing of measurement, nutritional and exercise status
[9].
The activation of hypothalamus-pituitary-adrenal (HPA) axis is
a most extensively investigated parameter in MDD; an altered
function of the HPA axis as well as the corticotrophin releasing
hormone (CRH) system have been consistently found in subjects
with MDD [10]. Patients with MDD have elevated cortisol levels
in plasma as well as elevated cortisol response to combined test
dexamethasone/CRH [11]. However, the activation of HPA axis
in depressed patients appears to be dependent on several factors,
including melancholic and atypical features, chronicity, cytokine
involvement and genetic traits; therefore, depressed patients do
not show an HPA axis hyperactivity in as much as 27–32% of the
cases [12,13].
In this study, we investigated the proinflammatory activation of
monocytes isolated from unmedicated depressed patients and in
healthy controls. We also evaluated the status of activation of HPA
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axis by salivary cortisol circadian rhythm and after low dose
dexamethasone suppression test.
Materials and Methods
Subjects
Ten drug-free outpatients who met the DSM-IV-TR criteria for
MDD were recruited at the Day Clinic of the Institute of
Psychiatry of the Catholic University in Rome during a Major
Depressive Episode (MDE), without psychotic features. The Mini-
International Neuropsychiatric Interview (M.I.N.I.) was conducted
to confirm the diagnosis of MDD and rule out bipolarity or other
exclusionary comorbid axis I disorders [14]. Patients underwent
psychiatric, physical and laboratory examinations to evaluate
blood cell count as well as liver, kidney and thyroid function.
Exclusion criteria were the presence of: concurrent psychiatric
illnesses (psychotic disorders, eating disorders, personality disor-
ders, mental retardation, anxiety disorders -except for specific
phobia-, mental disorders due to a general medical condition);
smoking history or substance abuse in the previous six months;
history of seizures; current liver, kidney or heart disease; neoplastic
diseases; neurological disorders; chronic pain; allergic reactions or
infection in the previous four weeks; AIDS; autoimmune diseases.
Underweight (BMI,18.5) or overweight (BMI$25) patients
suffering from endocrine, immune or metabolic disorders were
also excluded. Similarly, individuals who attempted suicide in the
previous six months were excluded. However, it was not possible
to rule out, as possible causes of immune system alterations, the
effects exerted by sleep deprivation and physical or psychological
stress, which are all frequent in depressed patients. In the patient
group, 6 were drug-naı¨ve and 4 had taken antidepressants that had
been discontinued at least 2 weeks prior to enrolment.
All patients underwent a psychometric assessment by the same
trained physician, blind to diagnosis, using the Italian version of
the 21-item Hamilton Depression Rating Scale (HDRS). This
scale provides a simple and reliable way to quantitatively assess the
magnitude and frequency of the patient’s depressive symptoms
and to document changes in time. Of the 21 items, 10 are rated on
a 5-point scale (0–4), 2 on a 4-point scale (0–3) and the remaining
9 on a 3-point scale (0–2). Levels of severity for most items are well
defined. The following cut-off scores identify growing levels of
depression severity: 8–17 mild depression; 18–24 moderate
depression; $25 severe depression [15].
Before starting the pharmacological treatment a blood sample
for laboratory testing was collected. Blood sampling was carried
out at 8 a.m., after an overnight fasting. All patients were then
treated with an antidepressant mono-therapy. Escitalopram, a
Selective Serotonin Reuptake Inhibitor (SSRI), was started at the
dose of 10 mg per day. Seven out of 10 patients required a dose
adjustments to 20 mg per day. Both treatment schedules are
included in the SmPC of the drug. Every patient was regularly
reviewed and HDRS scale was administered by the same rater,
blind to treatment, at each follow-up visit (after two weeks, one
month, three months and eight months) to assess treatment
outcome. We considered ‘responders’ all subjects with a 50%
decrease on total HDRS score and the dosage of escitalopram was
increased up to 20 mg per day, during the first two weeks, if a
treatment response was not achieved. During the last visit (after
eight months), a second blood sample for laboratory testing was
collected as previously described.
Finally, 10 subjects were recruited as healthy controls with a
BMI between 18.5 and 25 kg/m2 and without any kind of medical
condition. Based on the M.I.N.I., axis I psychiatric disorders were
excluded. They were non-smokers neither receiving medication
nor abusing of other substances.
The study was approved by the institutional review board. All
subjects gave their informed consent and possible side effects were
fully explained.
Isolation of peripheral blood mononuclear cell subsets
Human peripheral blood mononuclear cells (PBMC) were
obtained from EDTA peripheral blood by density gradient
centrifugation using the Ficoll-Paque Premium. Blood cell count
from both the depressed patients and the controls did not show
abnormal values and no significant differences were observed
between groups for monocyte count (0.3660.09 vs.
0.4660.156106 cells/ml; F = 3.54, n.s. difference). After two
washes with balanced salt solution, the cells were resuspended in
culture medium RPMI-1640 supplemented with 2 mM L-gluta-
mine, 100 UI/ml penicillin/streptomycin and 10% heat inacti-
vated FCS (Gibco Brl, Invitrogen Corporation, Paisley, UK) and
were plated at density of 46106 cells/well on a highly
immunoadsorbent plates to facilitate monocyte adhesion (Corning
CellBIND Surface). After 3 hours of incubation at 37uC in a 95%
O2/5% CO2 humidified atmosphere, lymphocytes were removed,
by washing the plates twice with PBS and monocytes were further
incubated overnight. After this incubation period, monocytes were
treated with medium alone RPMI-1640 or with 100 ng/ml
endotoxin bacteria (LPS) for 24 h; the parameters concentration
and time of exposure were set according to our previous
experience with other cellular models, as well as to data from
literature [16]. At the end of the experiment the medium was
collected for the PGE2 assessment.
mRNA analysis in real time PCR
Total cytoplasmic RNA was extracted using the RNeasy Micro
kit (Qiagen, Hilden, Germany), which included 15 min DNAse
treatment. RNA concentration was measured using the Quant-
iTTM RiboGreenH RNA Assay Kit (Invitrogen Corporation,
Carlsbad, CA, USA). A standard curve in the range of 0–10 ng
was run in each assay using 16S and 23S ribosomal RNA (rRNA)
from E. Coli as standard and provided by the kit. Aliquots (0.1 mg)
of RNA were converted to cDNA using random hexamer primers.
Quantitative changes in mRNA levels were estimated by real time
PCR (Q-PCR) using the following cycling conditions: 40 cycles of
denaturation at 95uC for 20 s; annealing at 60uC for 30 s; and
extension at 72uC for 30 s; using the Brilliant SYBR Green QPCR
Master Mix 26 (Stratagene, La Jolla, CA, USA). PCR reactions
were carried out in a 20 mL reaction volume in a MX3000P real
time PCR machine (Stratagene). Primers used for the evaluation of
gene expression are b-actin 471F (59-ACG TTG CTA TCC AGG
CTG TCC AT-39) and 711R (59-TTA ATG TCA CGC ACG
ATT TCC CGC-39) which yield a 241 base pair (bp) product;
human COX2 1381F (59-TTG CTG GCA GGG TTG CTG
GTG GTA-39), and 1466R (59CAT CTG CCT GCT CTG GTC
AAT CGA A-39) which yield a 86 bp product; human IL-6 49F
(59GGC TCA TTC TGC CCT CGA GCC-39) and 148R
(39GGA CCG AAG GCG CTT GTG GAG-59) which yield a
100 bp product; human IL-1b 84F (59AGC CAT GGC AGA
AGT ACC GT39) and 302R (59TCC ATG GCC ACA ACA
ACT GA 39) which yield a 219 bp product; and human toll-like
receptor 4 (TLR4) 25F (59-GCC ACT GGT CTG CAG GCG
TT-39), and 401R (39- TAG GAA CCA CCT CCA CGC AGG
G-59) which yield a 377 bp product; Relative mRNA concentra-
tions were calculated from the take-off point of reactions (threshold
cycle, Ct) using the comparative quantization method performed
by Stratagene software and based upon the 2DDCt method. This
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analysis approximates a given sample’s target mRNA (e.g. COX2)
level relative to the mean of the target mRNA levels in untreated
controls (‘‘calibrator’’ value), thus permitting statistical analysis of
deviation from the mean even among the controls. Ct values for b-
actin expression served as a normalizing signal. In each assay, the
PCR efficiency was also calculated using serial dilution of one
experimental sample; efficiency values between 94 and 98% were
found for each primer set and taken into account for the
comparative quantization analysis [17].
PGE2 assay
PGE2 levels in the incubation medium were detected using a
specific Enzyme Immunoassay kit (EIA) for PGE2, carried out
according to the manufacturer’s instructions (Assay Design, Inc.,
Ann Arbor, MI, USA). Briefly, the medium was collected from the
monocyte cultures, aliquoted and stored at 280uC until the day of
the assay (avoiding repeated freeze-thaw cycles). A standard curve
was generated during each assay in the concentration range 7.81–
1.000 pg/ml using the PGE2 standard provided in the kit and a
best fit curve was plotted. The minimum detectable concentration
of PGE2 was 7.81 pg/ml.
Salivary cortisol circadian rhythm and after low dose
dexamethasone suppression test
Salivary cortisol circadian rhythm and after low dose dexa-
methasone suppression test was performed in healthy subjects and
in MDD patients during the first evaluation and after a 8 months
treatment. Salivary samples were collected at 8 a.m., 4 p.m., 11
p.m. using the a commercially available device (Salivette, Sarstedt;
cotton swab without preparation). Low dose dexamethasone
suppression test was performed administering dexamethasone
1 mg per os at 11 p.m. and collecting salivary samples the
following day at 8 a.m. Salivary samples were centrifuged at 4u C
for 10 minutes and stored at 220u C until assayed. Salivary
cortisol concentration was determined by an elettrochemilumines-
cence (ECLIA) Roche method on Modular E without pretreat-
ment of the samples.
Statistical analysis
Results are shown as mean6 standard error of 10 replicates per
each group, as indicated in Figure legend. Data were analyzed by
ANOVA, Student’s t-test or Mann-Whithney U-test where
appropriate, using a PrismTM computer program (GraphPad,
San Diego, CA, USA). P values,0.05 were considered significant.
Stata2 program was used to calculate the study power.
Results
No significant differences were identified between patients and
healthy controls with regard to basic demographic data including
age (controls tended to be younger; t test: p = 0.07) and gender.
Table 1 shows demographic parameters, psycho-pathological
severity and treatment outcome of depressed patients. Most of
them showed a mild to moderate depressive symptomatology at
basal evaluation. One month after the antidepressant treatment a
significant reduction in HDRS scores was observed (data not
shown) and 8 patients showed a 50% decrease in their psycho-
pathological burden. All of the patients who achieved a response
after 1 month of treatment also maintained a favourable clinical
outcome during the entire study duration.
Primary cultures of monocytes from both controls and MDD
patients released sizable amounts of PGE2 under basal conditions
(Fig. 1). No significant difference was observed either between
controls and patients at time 0, or between patients assessed at
time 0 and after 8 months of follow-up (Fig. 1). Interestingly, a 24-
h incubation with endotoxin caused an average 123.3-fold increase
in PGE2 production by monocytes from healthy controls
compared to the previous 24 hrs of incubation, whereas only an
average 8.62-fold increase was detected in cells harvested from
drug-free patients (Controls vs patients 0; Student’s t-test
p = 0.0023; t = 3.546) (Fig. 2). After 8 months of follow-up, the
ability of monocytes from MDD patients to respond to the
endotoxin challenge appeared to be partially restored (Patients
time 0 vs patients F.U.; Mann Whitney test, p = 0.0185), since an
average 28-fold increase was measured, although such response
remained significantly lower compared to healthy controls
(Controls vs patients F.U.; Student’s t-test p = 0.0097; t = 2.895)
(Fig. 2). However, no significant correlation was found between
the changes in HDRS scores measured in the time-frame 0–8
months and the increased response to endotoxin observed in the
same time interval. Similar to PGE2, a huge (151.9-fold) increase
was observed in COX2 gene expression by monocytes from
controls, compared to a 38.8-fold increase in monocytes from
drug-free patients (Controls vs patients 0; Student’s t-test
p = 0.0024; t = 3.206). This value increased to 98.9-fold at 8-
month FU (Fig. 3) (Patients time 0 vs patients F.U. Student’s t-test
p = 0.0005; t = 3.733).
The other mediators of inflammation investigated here, IL-1 b
and -6 showed an opposite behaviour compared to the prostanoid
system after the LPS challenge. At baseline, cytokine gene
expression was markedly increased in drug-naı¨ve MDD patients
compared to healthy controls; however, because of the much
higher variability of this parameter compared to both PGE2 and
COX-2, the difference did not reach statistical significance (Fig. 4
and 5). Likewise, the high variability prevented to show a
significant difference between IL-1 b and -6 mRNA levels assessed
in patients at time 0 and after FU, although a strong trend to a
reduction was observed (Fig. 4 and 5). Limited to the comparison
between MMD patients and healthy controls at baseline, we also
measured plasma levels of C-Reactive Protein (CRP), and found
no significant differences (data expressed as mg/l of human serum
CRP, the means 6 SEM of 10 observations per group. MMD
patients: 1.3460.30; healthy controls: 1.2760.59).
In order to investigate the mechanisms underlying the LPS
effects in this paradigm, we assessed on our samples the gene
expression of TLR-4, i.e. the LPS receptor subtype expressed in
human monocytes [18]. We found a tiny increase in gene
expression both in Controls and MDD patients, with no significant
difference whatsoever (data not shown).
It was also interesting to investigate whether the above
described changes in inflammatory parameters could be related
to changes in HPA axis function in MDD patients; in particular, a
putative increase in glucocorticoid levels would tonically inhibit
COX-2 gene expression in monocytes. However, we found no
differences among the profiles of daily cortisol secretions in healthy
controls and MDD patients at time 0, as well as in patients after 8
months of follow-up (Fig. 6). A dexamethasone suppression test
carried out in both experimental groups showed that all of the
healthy volunteers had the HPA suppressed (11 p.m. salivary
cortisol ,0.1 mg/dl; salivary cortisol after low dose dexametha-
sone suppression test ,0.06 mg/dl), whereas 3 out of 10 patients
resulted to be non-suppressor (11 p.m. salivary cortisol .0.1 mg/
dl; salivary cortisol after low dose dexamethasone suppression test
.0.06 mg/dl), so they remained after 8 months of follow-up (data
not shown).
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Discussion
In this study we were seeking for a marker of inflammation in
depressed patients that was possibly not influenced by such
confounds as time of day, nutritional and exercise status or the age
and gender of patients. With this in mind, we investigated the
proinflammatory activation of monocytes isolated by depressed
patients. After 24-h incubation under basal conditions, cells were
exposed for 24-h to endotoxin. Looking at COX-2 gene expression
and prostanoid production, we found that cells from depressed
patients are significantly less reactive compared to monocytes
obtained from healthy controls. Such huge difference was only
partially reversed after 8 months of sustained treatment response.
On the contrary, IL-1b and -6 gene expression tended to be higher
in patients compared to controls at baseline, and it was blunted
after 8 months of treatment with escitalopram, although none of
the above changes was statistically different with respect to the
controls because of apparently higher variability of cytokine
mRNA levels in both experimental groups. We also evaluated the
status of activation of HPA axis by salivary cortisol circadian
rhythm and after low dose dexamethasone suppression test. In
fact, several observations of hypersecretion of CRH and cortisol
and of reduced HPA axis feedback from glucocorticoids in MDD
patients have been described [19].
The patients described in this report were the first consecutive
MDD patients enrolled in a larger clinical trial aimed to
investigate putative relationships between disease state and
response to treatment on the one hand, and immune-inflamma-
tory parameters on the other hand. This clinical trial is currently
ongoing; however, by analysing the first set of data and comparing
them with those from matched controls, we observed such a huge
difference in the PGE2 response to endotoxin challenge that,
despite the preliminary nature of our findings, we though
biologically and clinically plausible to draw some conclusions
based on such small subset of patients. It was also a statistically
plausible approach: with a population of 20 subjects, the study has
a power higher than 95% to detect a difference between the two
study groups, as far as PGE2 production and COX2 gene
expression are concerned.
From the viewpoint of HPA axis function, our MDD patients
also appear to be representative of a larger population. In fact, 3
(30%) out of 10 patients not suppressed at the dexamethasone
suppression test; this percentage is consistent with most of the data
reported in the literature. Vasavada and collaborators showed that
non suppression occurred in 27% of patients with MDD and in
43% of bipolar patients during depression phase [13]; similar data
have been reported by the group of Iacovides [12].
The profile of IL-1b and -6 gene expression in this experimental
paradigm was diverging from those of COX-2 and PGE2, since
the cytokine tended to be expressed to a higher level in MDD
patients at baseline compared to controls, and it was blunted
rather than increased by SSRI treatment. These findings are in
keeping with a large evidence reported in the literature [20,21,22].
However, the very high variability in cytokine mRNA levels
prevented to achieve statistically significant differences among
experimental groups. As mentioned before, this study is still
ongoing at present; a larger sample of population will probably
allow us to draw a conclusion about the putative different
regulation of IL-6 gene expression in MDD patients.
The pattern of inflammatory mediator gene expression and
production in blood cells from MDD patients has been recently
investigated by Myint and collaborator [23]. These authors
showed that a 72-hr exposure to 5 mg/ml endotoxin induced
significantly higher production of both IFN-c and IL-10 in blood
cells from normal controls compared to depressed patients. Based
on these findings, these authors postulate that depressed patients
Table 1. Demographic parameters, psycho-pathological severity and treatment outcome of depressed patients.
Demographic data
Patients Healthy controls
Mean ± SD(n) Mean ± SD(n)
Age (years) 48.40611.13 (10) 39.30610.06 (10)
Sex (F/M) 8/2 5/5
BMI (kg/m2) 24.7665.59 (10) 23.0962.03 (10)
Psychometric parameters
HDRS Scale Mean ± SD(n)
Basal 18.5063.41 (10) ,8 (10)
After 8 months 8.5066.20 (10)
Data are expressed as the means 6 SD (n = 10).
doi:10.1371/journal.pone.0052585.t001
Figure 1. Prostaglandin E2 release under basal conditions. Data
are expressed as pg/ml, the means 6 SEM of 10 subjects per group.
FU= Follow up.
doi:10.1371/journal.pone.0052585.g001
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present an increased immune-inflammatory response under basal
conditions, and the reduced response of blood cells to in vitro
stimulation reflects an exhaustion of cell function subsequent to
sustained hyperactivity. This hypothesis implies that a difference in
the production of pro-inflammatory mediators should be already
present under basal conditions; however, we observed no
difference in baseline PG production between MDD patients
and healthy controls. The lack of differences we observed under
basal conditions seems to contradict the hypothesis by Myint and
colleagues, but it might also be explained by the 24-hr washout we
carried out before starting the experiments.
The findings by Myint and colleagues, along with those
presented here, for the first time show a different regulation of
whole blood cells responses to inflammatory stimuli in depression.
Figure 2. Monocytes were activated for 24 hours with 100 ng/ml endotoxin. Data are expressed as PGE2 release, fold changes vs each
paired unstimulated control. (A) Data are the means 6 SEM (n= 10).**P,0.01 vs. healthy controls; (B) Individual data of patients 6P,0.05 vs patients
at time 0; Mann Whitney test. FU = Follow up.
doi:10.1371/journal.pone.0052585.g002
Figure 3. Total cytosolic RNA was prepared used for Q-PCR analysis of the expression of COX2. Data are expressed as fold changes vs
each paired unstimulated control, taken as calibrator for comparative quantitation analysis of mRNA levels. Each sample was measured in triplicate.
(A) Data are the means 6 SEM (n= 10).**P,0.01 vs. healthy controls; (B) Individual data of patients 666P,0.001 vs patients at time 0; Student’s t-test.
FU = Follow up.
doi:10.1371/journal.pone.0052585.g003
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Both reports are descriptive in nature, since it is currently difficult
to provide a mechanistic explanation to these phenomena. We can
hypothesize that factors controlling COX-2 (and perhaps IL-6)
gene expression are altered in MDD, resulting in both up- and
down-regulation of inflammatory mediator production. In our
study, the lack of a concomitant HPA impairment would suggest
that the glucocorticoid-GRE system is not involved. The diverging
pattern of gene expression of COX-2 compared to inflammatory
cytokines, all of which are inhibited by glucocorticoids [24,25],
would also exclude that the latter play any role. Here we also
tested the hypothesis that a deregulation occurs at the level of TLR
expression. However, we found no difference between TLR-4
gene expression in monocytes form healthy controls and patients,
and LPS produced the same mild increase in both groups,
suggesting that any difference in regulation occurring in depressed
patients is to be located somewhere downstream receptor
activation.
Conclusion
In conclusion, our findings clearly indicate that MDD patients
present an altered response of blood monocytes to a standardized
Figure 4. Total cytosolic RNA was prepared used for Q-PCR analysis of the expression of IL-6. Data are expressed as fold changes vs each
paired unstimulated control, taken as calibrator for comparative quantitation analysis of mRNA levels. Each sample was measured in triplicate. (A)
Data are the means 6 SEM (n= 10). (B) Individual data of patients. FU = Follow up.
doi:10.1371/journal.pone.0052585.g004
Figure 5. Total cytosolic RNA was prepared used for Q-PCR analysis of the expression of IL-1b. Data are expressed as fold changes vs
each paired unstimulated control, taken as calibrator for comparative quantitation analysis of mRNA levels. Each sample was measured in triplicate.
(A) Data are the means 6 SEM (n= 10). (B) Individual data of patients. FU= Follow up.
doi:10.1371/journal.pone.0052585.g005
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endotoxin challenge. This ex-vivo/vitro model appears to be a
promising marker of the immune dysreactivity associated to
depression. It appears to be independent from the time of day,
nutritional and exercise status, and HPA axis function. We also
observed differences in monocyte reactivity after a standard drug
treatment; however, the experimental design adopted here does
not allow to draw any conclusion as to whether monocyte
reactivity to endotoxin might also be used as a marker of the
outcome of pharmacological treatments, since a 8-month FU in
the group of healthy controls was not carried out.
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